Nature CommunicationsCancer BiologyPeer-reviewed journal article
Oncogenic context shapes the fitness landscape of tumor suppression
L. M. Blair, J. M. Juan, L. Sebastian, V. B. Tran, W. Nie, G. D. Wall, M. Gerceker, I. K. Lai, E. A. Apilado, G. Grenot, D. Amar, G. Foggetti, M. Do Carmo, Z. Ugur, D. Deng, A. Chenchik, M. Paz Zafra, L. E. Dow, K. Politi, J. J. MacQuitty, D. A. Petrov, M. M. Winslow, M. J. Rosen, I. P. Winters
Abstract
Tumors acquire alterations in oncogenes and tumor suppressor genes in an adaptive walk through the fitness landscape of tumorigenesis. However, the features of this landscape remain poorly understood and cannot be revealed by human cancer genotyping alone. Here, we use a multiplexed, autochthonous mouse platform to model and quantify the initiation and growth of more than one hundred genotypes of lung tumors across four oncogenic contexts: KRAS G12D, KRAS G12C, BRAF V600E, and EGFR L858R. The resulting fitness landscape is rugged (the effect of tumor suppressor inactivation often switches between beneficial and deleterious depending on the oncogenic context), shows no evidence of diminishing-returns epistasis within variants of the same oncogene, and is inconsistent with expectations of a simple linear signaling relationship among these three oncogenes. Our findings suggest that tumor suppressor effects are strongly context-specific, which limits the set of evolutionary paths that can be taken through the fitness landscape.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma
M. Yousefi, L. Andrejka, … G. Boross·bioRxiv·Jan 30, 2023
- Combinatorial in vivo genome editing identifies widespread epistasis during lung tumorigenesis
J. D. Hebert, Y. J. Tang, … M. M. Winslow·bioRxiv·Mar 7, 2024
- Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
G. Foggetti, C. Li, … K. Politi·Cancer DiscoveryPeer-reviewed·Mar 11, 2021
- Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
Collin M. Blakely, Thomas B.K. Watkins, … Trever G. Bivona·bioRxiv·Mar 16, 2017
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities
M. Yousefi, G. Boross, … M. M. Winslow·bioRxiv·Oct 20, 2021
- Passenger mutations can accelerate tumor suppressor gene inactivation in cancer evolution
D. Wodarz, A. Newell, N. Komarova·bioRxiv·Oct 13, 2017